A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Text and Data Mining valid from 2020-04-01
3 April 2020
Ethics approval and consent to participate
The authors declare that they have no competing interests.